✓ Independent editorial reviews of U.S. telehealth programs · Prices and dates shown on each page · Educational only — not medical advice
Cognitive · Peptide Reference

Selank

Released: Last reviewed:

Russian-developed synthetic heptapeptide derived from tuftsin. Anxiolytic without sedation or dependence; used clinically in Russia for generalized anxiety disorder. Limited Western clinical trials.

Cognitive Evidence grade: C Not FDA-approved
Researched By
Dr. Parmis
Medical Researcher · Western University of Health Sciences
Medically Reviewed By
Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)
Last medically reviewed: October 15, 2026 · This page is informational and does not constitute medical advice.

Key facts

Class
Synthetic heptapeptide (tuftsin analog)
Route
Intranasal
Pharmacy pathway
See the dated FDA status notice above
Clinical use (Russia)
Generalized anxiety disorder, asthenia
Mechanism
Modulates GABA, BDNF, enkephalin systems
Common dose
300 mcg intranasal 2-3x daily
Evidence grade
C (Russian clinical use)
FDA status
Not FDA-approved

Mechanism of action

Russian-developed synthetic heptapeptide derived from tuftsin. Anxiolytic without sedation or dependence; used clinically in Russia for generalized anxiety disorder. Limited Western clinical trials.

Standard dosing

Typical clinical use: 300 mcg intranasal 2-3x daily. Dosing varies by indication and provider protocol; this is reference-only and not a prescribing recommendation. Selank requires a prescription from a licensed clinician.

Regulatory status & pharmacy pathway

Not FDA-approved. FDA limits which peptides a pharmacy may compound; check this page’s dated FDA status notice before assuming a peptide is legally available. Ask which licensed pharmacy fills the prescription and check that pharmacy’s license with your state board of pharmacy.

U.S. telehealth providers prescribing Selank

The most commonly cited U.S. telehealth providers for Selank are Defy Medical, Marek Health, Hone Health, Maximus, and PeterMD —, whose offerings for this peptide we have not verified (see the FDA status notice above). See the full provider directory for complete profiles.

Trade-offs to know

Selank carries the trade-offs common to all compounded peptide therapeutics: not FDA-approved, cash-pay only, no in-network insurance coverage, and pharmacy-quality variation between providers. Choose a prescriber that names its pharmacy, explains its follow-up schedule and states the regulatory status of what it prescribes.

Related peptides in the cognitive category

Editorial team

Researched by Dr. Parmis (Medical Researcher, Western University of Health Sciences); medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP (FNP-BC).

References

  1. Medvedev VE, Tereshchenko OV, Israelyan AY, Chobanu IK. Optimization of treatment for anxiety and asthenic disorders in patients with cardiovascular diseases: results of administering the anxiolytic drug Selank. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(5):17-22. PMID: 25001774
  2. Zozulya AA, Neznamov GG, Siuniakov TS, et al. Efficacy and possible mechanisms of action of a new peptide anxiolytic drug Selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454102

Sources are peer-reviewed where available. PubMed (PMID) links resolve to NCBI's PubMed database. FDA links resolve to the U.S. Food and Drug Administration. Citations were last verified 2026-05-11.